NEW YORK, July 15, 2009 (GLOBE NEWSWIRE) -- Prana Biotechnology Limited (Nasdaq:PRAN) (ASX:PBT), today announced that its Head of Research, Assoc. Prof. Robert Cherny, presented new data on PBT2, the Company's lead compound in development for Alzheimer's disease, during the Hot Topics 2 session at the International Conference of Alzheimer's Disease (ICAD) in Vienna, Austria. The presentation was entitled "PBT2 ameliorates cognitive impairment in Alzheimer's disease transgenic and aged mice: Evidence for a common mechanism of action."
